UB Paderborn / Katalog / Suche / in CDI

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)

European journal of cancer (1990), 2015-09, Vol.51, p.S599-S599

2015

Volltextzugriff (PDF)

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Volltextzugriff (PDF)

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-10, Vol.373 (17), p.1627-1639

2015

Volltextzugriff (PDF)

Malignant Pleural Mesothelioma and Radiotherapy: Lung Toxicity Results of an Interim Analysis in Prospective Pilot Trial

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e46-e46

2023

Volltextzugriff (PDF)

Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy

Annals of oncology, 2019-04, Vol.30, p.ii63-ii64

2019

Volltextzugriff (PDF)

Role of TP53 mutations in relation to response to anti-ALK agents in EML4-ALK-translocated NSCLC patients

Annals of oncology, 2018-10, Vol.29, p.viii654-viii654

2018

Volltextzugriff (PDF)

1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial

Annals of oncology, 2021-09, Vol.32, p.S950-S950

2021

Volltextzugriff (PDF)

O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1152-S1153

2019

Volltextzugriff (PDF)

Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies

Annals of oncology, 2017-10, Vol.28, p.vi2-vi2

2017

Volltextzugriff (PDF)

51P Phase IB (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): Preliminary results

Immuno-oncology technology, 2023-12, Vol.20, p.100524, Article 100524

2023

Volltextzugriff (PDF)

Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies

Annals of oncology, 2017-09, Vol.28, p.v488

2017

Volltextzugriff (PDF)

Venous thromboembolic events in advanced adenocarcinoma of the lung: impact on prognosis according to platinum therapies and presence of driver mutations

Annals of oncology, 2015-10, Vol.26, p.vi83

2015

Volltextzugriff (PDF)

Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2017-09, Vol.28, p.v462

2017

Volltextzugriff (PDF)

High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment

Cancer radiothérapie, 2017-12, Vol.21 (8), p.766-773

2017

Volltextzugriff (PDF)

417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

Annals of oncology, 2015-12, Vol.26, p.ix125-ix125

2015

Volltextzugriff (PDF)

1536P - Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)

Annals of oncology, 2012-09, Vol.23, p.ix496-ix497

2012

Volltextzugriff (PDF)

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)

Annals of oncology, 2012-09, Vol.23, p.ix496-ix497

2012

Volltextzugriff (PDF)

Cmet Expression and Activity of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts): Exploratory Analysis of the Randomized Phase III Torch Trial

Annals of oncology, 2014-09, Vol.25, p.iv438

2014

Volltextzugriff (PDF)

Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur

Revue des maladies respiratoires actualités, 2020-01, Vol.12 (1), p.208-209

2020

Volltextzugriff (PDF)

1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv438-iv438

2014

Volltextzugriff (PDF)

P/CAF-mediated spermidine acetylation regulates histone acetyltransferase activity

Journal of enzyme inhibition and medicinal chemistry, 2016-11, Vol.31 (sup3), p.75-82

2016

Volltextzugriff (PDF)

65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

Immuno-oncology technology, 2022-12, Vol.16, p.100170, Article 100170

2022

Volltextzugriff (PDF)

Comparison of the frequency of atopic diseases in children with severe and partial IgA deficiency

International archives of allergy and applied immunology, 1987, Vol.82 (3-4), p.485

1987

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Malignant Pleural Mesothelioma and Radiotherapy: Lung Toxicity Results of an Interim Analysis in Prospective Pilot Trial

Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy

Role of TP53 mutations in relation to response to anti-ALK agents in EML4-ALK-translocated NSCLC patients

1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial

O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response

Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies

51P Phase IB (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): Preliminary results

Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies

Venous thromboembolic events in advanced adenocarcinoma of the lung: impact on prognosis according to platinum therapies and presence of driver mutations

Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment

417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

1536P - Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)

Cmet Expression and Activity of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts): Exploratory Analysis of the Randomized Phase III Torch Trial

Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur

1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL

P/CAF-mediated spermidine acetylation regulates histone acetyltransferase activity

65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

Comparison of the frequency of atopic diseases in children with severe and partial IgA deficiency

Suchergebnisse filtern